Is Orforglipron (Foundayo) FDA Approved?
DrugStatusIndex provides a clear, data-driven view of the regulatory status of medications, compounds, and related products. This page explains whether Orforglipron (Foundayo) is FDA approved and how it is commonly categorized.
Overview
Orforglipron, sold under the brand name Foundayo, is an oral GLP-1 receptor agonist developed by Eli Lilly for chronic weight management. It is a once-daily pill designed for adults with obesity or overweight plus weight-related medical conditions.
FDA Status Details
Orforglipron (Foundayo) is classified as FDA Approved. The FDA approved Foundayo on April 1, 2026 for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity. :contentReference[oaicite:0]{index=0}
Approved Use
Foundayo is approved for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and help maintain long-term weight reduction. It is the first small-molecule oral GLP-1 approved for this purpose. :contentReference[oaicite:1]{index=1}
Unique Advantage
Unlike some other oral GLP-1 medications, Foundayo can be taken any time of day without food or water restrictions, making it a more flexible option for many patients. :contentReference[oaicite:2]{index=2}
Search Another Drug or Compound
Use DrugStatusIndex to review public regulatory status information for medications, compounds, and related products.